Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
Kote-Jarai Z., Olama AAA., Giles GG., Severi G., Schleutker J., Weischer M., Campa D., Riboli E., Key T., Gronberg H., Hunter DJ., Kraft P., Thun MJ., Ingles S., Chanock S., Albanes D., Hayes RB., Neal DE., Hamdy FC., Donovan JL., Pharoah P., Schumacher F., Henderson BE., Stanford JL., Ostrander EA., Sorensen KD., Dörk T., Andriole G., Dickinson JL., Cybulski C., Lubinski J., Spurdle A., Clements JA., Chambers S., Aitken J., Gardiner RAF., Thibodeau SN., Schaid D., John EM., Maier C., Vogel W., Cooney KA., Park JY., Cannon-Albright L., Brenner H., Habuchi T., Zhang H-W., Lu Y-J., Kaneva R., Muir K., Benlloch S., Leongamornlert DA., Saunders EJ., Tymrakiewicz M., Mahmud N., Guy M., O'Brien LT., Wilkinson RA., Hall AL., Sawyer EJ., Dadaev T., Morrison J., Dearnaley DP., Horwich A., Huddart RA., Khoo VS., Parker CC., Van As N., Woodhouse CJ., Thompson A., Christmas T., Ogden C., Cooper CS., Lophatonanon A., Southey MC., Hopper JL., English DR., Wahlfors T., Tammela TLJ., Klarskov P., Nordestgaard BG., Røder MA., Tybjærg-Hansen A., Bojesen SE., Travis R., Canzian F., Kaaks R., Wiklund F., Aly M., Lindstrom S., Diver WR., Gapstur S., Stern MC., Corral R., Virtamo J., Cox A., Haiman CA., Le Marchand L., Fitzgerald L., Kolb S., Kwon EM., Karyadi DM., Orntoft TF., Borre M., Meyer A., Serth J., Yeager M., Berndt SI., Marthick JR., Patterson B., Wokolorczyk D., Batra J., Lose F., McDonnell SK., Joshi AD., Shahabi A., Rinckleb AE., Ray A., Sellers TA., Lin H-Y., Stephenson RA., Farnham J., Muller H., Rothenbacher D., Tsuchiya N., Narita S., Cao G-W., Slavov C., Mitev V., Easton DF., Eeles RA., UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology None., UK ProtecT Study Collaborators, The Australian Prostate Cancer BioResource None., PRACTICAL Consortium None.
Prostate cancer (PrCa) is the most frequently diagnosed male cancer in developed countries. We conducted a multi-stage genome-wide association study for PrCa and previously reported the results of the first two stages, which identified 16 PrCa susceptibility loci. We report here the results of stage 3, in which we evaluated 1,536 SNPs in 4,574 individuals with prostate cancer (cases) and 4,164 controls. We followed up ten new association signals through genotyping in 51,311 samples in 30 studies from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. In addition to replicating previously reported loci, we identified seven new prostate cancer susceptibility loci on chromosomes 2p11, 3q23, 3q26, 5p12, 6p21, 12q13 and Xq12 (P = 4.0 × 10(-8) to P = 2.7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified.